EMPLOYMENT AGREEMENTEmployment Agreement • October 8th, 2024 • OptiNose, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledOctober 8th, 2024 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of October 7, 2024 (the “Effective Date”), by and between OptiNose US, Inc., a Delaware corporation (“OptiNose US”) and wholly-owned subsidiary of OptiNose, Inc. (the “Parent” and, together with OptiNose US, the “Company”), and Paul Terence Kohler, Jr. (“Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2023 • OptiNose, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledMay 11th, 2023 Company Industry JurisdictionThis AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of May 9, 2023 (the “Effective Date”), by and between OptiNose US, Inc., a Delaware corporation (“OptiNose US”) and wholly-owned subsidiary of OptiNose, Inc. (the “Parent” and, together with OptiNose US, the “Company”), and Michael Marino (“Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2023 • OptiNose, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledMay 11th, 2023 Company Industry JurisdictionThis AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of May 9, 2023 (the “Effective Date”), by and between OptiNose US, Inc., a Delaware corporation (“OptiNose US”) and wholly-owned subsidiary of OptiNose, Inc. (the “Parent” and, together with OptiNose US, the “Company”), and Ramy A. Mahmoud (“Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2023 • OptiNose, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledMay 11th, 2023 Company Industry JurisdictionThis AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of May 9, 2023 (the “Effective Date”), by and between OptiNose US, Inc., a Delaware corporation (“OptiNose US”) and wholly-owned subsidiary of OptiNose, Inc. (the “Parent” and, together with OptiNose US, the “Company”), and Paul Spence (“Executive”).